Kamada Ltd. to Release Q4 and Full-Year 2024 Results on March 5

Kamada Ltd . (NASDAQ:KMDA), a pharmaceutical company specializing in the development of plasma-derived protein therapeutics, has announced that it will release its financial results for the fourth quarter and fiscal year 2024 on March 5, 2025. The report will provide investors with a comprehensive overview of the company’s financial performance and may influence the company’s stock price. According to InvestingPro data, the company has demonstrated strong financial health with a "GREAT" overall score, making this upcoming earnings release particularly significant for investors.

The announcement, made today, was in accordance with a 6-K form filed with the Securities and Exchange Commission (SEC). 6-K forms are submitted by foreign private issuers to provide the SEC with periodic updates on significant corporate events. The document also confirmed that Kamada Ltd. files annual reports under Form 20-F, which is a submission required for foreign private issuers with listed equity shares on American exchanges.

Kamada Ltd., headquartered in Rehovot, Israel, operates internationally in the pharmaceutical preparations sector under the organization name 03 Life Sciences. The company’s focus is on the development, production, and marketing of specialty life-saving therapeutics. With trailing twelve-month revenue of $158.38 million and a healthy gross profit margin of 42.5%, the company has maintained solid operational performance. InvestingPro analysis reveals 8 additional key insights about KMDA’s financial position and growth prospects, available to subscribers.

Investors and analysts often scrutinize quarterly and annual financial statements to assess a company’s health and prospects. The upcoming release will cover the period ending December 31, 2024, and will be closely watched by stakeholders interested in Kamada’s performance and future outlook. Recent analyst consensus shows high confidence in KMDA’s potential, with price targets ranging from $11 to $20 per share. The company’s strong current ratio of 4.84 and minimal debt-to-equity ratio of 0.04 suggest robust financial stability.

The financial results will be incorporated by reference into the Registrant’s Form S-8 Registration Statements, which are used by public companies to register securities to be offered to employees under employee stock purchase, savings, option, bonus, appreciation rights, or similar plans.

This announcement is based on a press release statement and investors are advised to review the full financial results on March 5, 2025, to gain a complete understanding of Kamada Ltd.’s financial position and future direction. For detailed analysis and comprehensive insights, investors can access KMDA’s full Pro Research Report, available exclusively on InvestingPro, which includes in-depth valuation metrics, growth indicators, and expert analysis of the company’s market position.

In other recent news, Kamada Ltd. has secured a $25 million contract for the supply of its products in Latin America. The agreement, set to last three years, involves providing KAMRAB® and VARIZIG® to undisclosed parties in the region. KAMRAB® is used for rabies post-exposure prophylaxis, while VARIZIG® is utilized for post-exposure treatment of varicella. This contract, announced through a Form 6-K filing with the U.S. Securities and Exchange Commission, highlights Kamada’s efforts to expand its global presence. The development signifies a significant step for Kamada in the international healthcare market. While details of the parties involved remain confidential, the contract reflects the demand for Kamada’s specialized pharmaceutical products. The company’s Vice President General Counsel and Corporate Secretary, Nir Livneh, ensured the accuracy of the report. This recent development could be seen as a positive indicator of Kamada’s business prospects and operational growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.